Disease Domain | Count |
---|---|
Nervous System Diseases | 13 |
Endocrinology and Metabolic Disease | 7 |
Infectious Diseases | 3 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 12 |
Small molecule drug | 2 |
AAV based gene therapy | 1 |
Single-chain FV antibody fragment | 1 |
Antibody | 1 |
Target |
Mechanism TTR inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SOD1 inhibitors |
Active Org. |
Originator Org. AL-S Pharma AGStartup [+1] |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism mAChRs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date08 Oct 2020 |
Sponsor / Collaborator |
Start Date10 Feb 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
NI-004 ( mAChRs ) | Alzheimer Disease More | Phase 2 |
NI-005 ( SOD1 ) | Amyotrophic Lateral Sclerosis More | Phase 2 |
NI004/NSC001 | Alzheimer Disease More | Phase 1 |
BIIB-076 | Alzheimer Disease More | Phase 1 |
NI-006 ( TTR ) | Transthyretin Amyloid Cardiomyopathy More | Phase 1 |